{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:25:48Z","timestamp":1794306348415,"version":"4.9.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.euo.2023.11.013","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T02:13:19Z","timestamp":1701828799000},"page":"870-876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective?"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3710-014X","authenticated-orcid":false,"given":"Niranjan J.","family":"Sathianathen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badrinath","family":"Konety","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun A.","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niall M.","family":"Corcoran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien M.","family":"Bolton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2023.11.013_b0005","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2023.11.013_b0010","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.11.013_b0015","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00a0\u00d7\u00a02 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2023.11.013_b0020","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2023.11.013_b0025","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nrclinonc.2017.31","article-title":"The high price of anticancer drugs: origins, implications, barriers, solutions","volume":"14","author":"Prasad","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.euo.2023.11.013_b0030","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.euo.2019.01.004","article-title":"A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer","volume":"2","author":"Sathianathen","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2023.11.013_b0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2023.11.013_b0040","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2023.11.013_b0045","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.urolonc.2022.10.016","article-title":"Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: an updated systematic review and network meta-analysis","volume":"41","author":"Sathianathen","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2023.11.013_b0050","unstructured":"US Department of Veterans Affairs. VA federal supply schedule service. https:\/\/www.fss.va.gov."},{"key":"10.1016\/j.euo.2023.11.013_b0055","unstructured":"Tufts Medical Center. Cost-effectiveness analysis (CEA) registry. https:\/\/cear.tuftsmedicalcenter.org."},{"key":"10.1016\/j.euo.2023.11.013_b0060","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JCO.21.00728","article-title":"Quality of life in men with prostate cancer randomly allocated to receive docetaxel or abiraterone in the STAMPEDE trial","volume":"40","author":"Rush","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.11.013_b0065","unstructured":"Australian Government Department of Health and Aged Care. The pharmaceutical benefits scheme 2023. https:\/\/www.pbs.gov.au\/pbs\/home."},{"key":"10.1016\/j.euo.2023.11.013_b0070","unstructured":"Joint Formulary Committee, editors. British national formulary 2023. London, UK: Royal Pharmaceutical Society; 2023."},{"key":"10.1016\/j.euo.2023.11.013_b0075","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1177\/0272989X15575286","article-title":"Estimating the expected value of sample information using the probabilistic sensitivity analysis sample: a fast, nonparametric regression-based method","volume":"35","author":"Strong","year":"2015","journal-title":"Med Decis Making"},{"key":"10.1016\/j.euo.2023.11.013_b0080","doi-asserted-by":"crossref","first-page":"1717030","DOI":"10.1080\/20016689.2020.1717030","article-title":"Understanding the global measurement of willingness to pay in health","volume":"8","author":"McDougall","year":"2020","journal-title":"J Mark Access Health Policy"},{"key":"10.1016\/j.euo.2023.11.013_b0085","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2022.11.002","article-title":"Management of patients with advanced prostate cancer. Part I: intermediate-\/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the Advanced Prostate Cancer Consensus Conference 2022","volume":"83","author":"Gillessen","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.11.013_b0090","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.urolonc.2019.05.017","article-title":"Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone na\u00efve prostate cancer","volume":"37","author":"Ramamurthy","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2023.11.013_b0095","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jamaoncol.2016.4166","article-title":"Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines","volume":"3","author":"Salas-Vega","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2023.11.013_b0100","doi-asserted-by":"crossref","first-page":"e2033004","DOI":"10.1001\/jamanetworkopen.2020.33004","article-title":"Assessment of Food and Drug Administration- and European Medicines Agency-approved systemic oncology therapies and clinically meaningful improvements in quality of life: a systematic review","volume":"4","author":"Arciero","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2023.11.013_b0105","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.2217\/fon-2021-1282","article-title":"Financial toxicity and its impact on health outcomes and caregiver burden among adult cancer survivors in the USA","volume":"18","author":"Inguva","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.euo.2023.11.013_b0110","doi-asserted-by":"crossref","first-page":"e0196007","DOI":"10.1371\/journal.pone.0196007","article-title":"Assessment of costs associated with adverse events in patients with cancer","volume":"13","author":"Wong","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.euo.2023.11.013_b0115","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1464-410X.2012.11597.x","article-title":"Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis","volume":"111","author":"Cooperberg","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2023.11.013_b0120","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","article-title":"Health state utilities for metastatic breast cancer","volume":"95","author":"Lloyd","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2023.11.013_b0125","doi-asserted-by":"crossref","first-page":"367.e7","DOI":"10.1016\/j.urolonc.2020.12.014","article-title":"Patients\u2019 preferences for delaying metastatic castration-resistant prostate cancer: combining health state and treatment valuation","volume":"39","author":"Rentz","year":"2021","journal-title":"Urol Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112300278X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112300278X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T09:36:23Z","timestamp":1794303383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258893112300278X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S258893112300278X"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2023.11.013","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective?","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2023.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}